Potential of cannabinoids in the treatment of hepatocellular carcinoma

Autores

  • Alistan Farias
  • Rafael Maas
  • Pedro Souza
  • Millena Boguchewski
  • Camila Marques

Palavras-chave:

Cannabinoids, Hepatocellular carcinoma, Hepatic Neoplasia

Resumo

In 1964 the Δ9-Tetrahydrocannabinol was isolated and identified for the first time by Gaoni and Mechoulam. After 26 years, in 1990, the CB1 and CB2 receptors responsible for the action of these cannabinoids were identified, as well as the endogenous substances, derived from arachidonic acid, related to their activation (anandamide and 2-AG). The CB1 receptor is more present in presynaptic neurons, and is responsible for the great majority of the neurobehavioral effects of cannabinoids through a mechanism of inhibition of neurotransmitter release (regulating the action of ion channels). The CB2 receptor is mainly found on the immune system cells, where it acts modulating the release of cytokines.

 

DOI: 10.56238/homeinternationalanais-072

 

Publicado

2023-02-01

Como Citar

Farias, A., Maas, R., Souza, P., Boguchewski, M., & Marques, C. (2023). Potential of cannabinoids in the treatment of hepatocellular carcinoma. Caderno De ANAIS HOME. Recuperado de https://homepublishing.com.br/index.php/cadernodeanais/article/view/74